Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development

Fatemeh Azizian-Farsani1, Navid Abedpoor2, Mohammad Hasan Sheikhha1

  • 1Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Frontiers in Oncology
|October 29, 2020
PubMed

Insights

Receptor for advanced glycation end-products (RAGE) drives colorectal cancer (CRC) progression through inflammatory signaling pathways. Targeting RAGE and its ligands may offer new therapeutic strategies for CRC, especially in diabetic patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • Immunology

Background:

  • Receptor for advanced glycation end-products (RAGE) is a transmembrane protein involved in chronic inflammation.
  • RAGE acts as a pattern recognition receptor, binding damage-associated molecular patterns like HMGB1, S100 proteins, and AGEs.
  • RAGE activation triggers intracellular signaling, promoting colorectal carcinoma (CRC) progression.

Purpose of the Study:

  • To review downstream signaling cascades activated by RAGE in CRC.
  • To summarize RAGE ligands, their sources, and clinical relevance in the inflammatory tumor microenvironment.
  • To investigate the role of RAGE in CRC patients with diabetes mellitus.

Main Methods:

  • Literature review of RAGE signaling pathways in CRC.
  • Analysis of RAGE expression and its correlation with colon cancer cell survival.
  • Investigation of RAGE's role in tumorigenesis within the tumor microenvironment.

Main Results:

  • RAGE activation leads to numerous intracellular signaling pathways, including AP-1, NF-κB, STAT3, Smad4, MAPK, mTOR, PI3K, RAS, Wnt/β-catenin, and GSK3β.
  • RAGE expression correlates with colon cancer cell survival and tumorigenesis.
  • The RAGE pathway plays a significant role in CRC, particularly in the context of inflammation and diabetes.

Conclusions:

  • RAGE signaling is a key driver of colorectal carcinoma progression.
  • Understanding RAGE-ligand interactions and downstream pathways is crucial for CRC therapy.
  • Targeting RAGE offers potential therapeutic avenues for CRC, especially in comorbid diabetic patients.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K